Cellyan Biotechnology (HKPD) Receivables - Net (2024 - 2026)
Cellyan Biotechnology (HKPD) posted quarterly Receivables - Net of $5.1 million for Q3 2025, up 4.36% year-over-year from $4.9 million in Q3 2024, and up 9.39% quarter-over-quarter from $4.7 million in Q1 2025.
Cellyan Biotechnology (HKPD) Receivables - Net (2024 - 2026) Analysis & Trends
Cellyan Biotechnology (HKPD) has reported Receivables - Net for 2 consecutive years, with $5.1 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Receivables - Net rose 4.36% year-over-year to $5.1 million; the TTM figure through Sep 2025 stood at $5.1 million (up 4.36% YoY), while the FY2025 annual figure was $4.7 million, up 25.88% from the prior year.
- Receivables - Net rose to $5.1 million in Q3 2025 per HKPD's latest filing, from $4.7 million in the prior quarter.
- Across five years, Receivables - Net topped out at $5.1 million in Q3 2025 and bottomed at $3.7 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Mckesson | 102.57 Bn | 97.41 Bn | 3.69 Bn |
| 2 | Cencora | 61.35 Bn | 58.53 Bn | 3.61 Bn |
| 3 | Cardinal Health | 54.15 Bn | 49.30 Bn | 2.56 Bn |
| 4 | Henry Schein | 10.05 Bn | 9.89 Bn | 1.10 Bn |
| 5 | Akso Health | 671.90 Mn | 671.70 Mn | - |
| 6 | Edap Tms | 154.62 Mn | 133.07 Mn | 7.34 Mn |
| 7 | Accendra Health | 90.69 Mn | 83.04 Mn | 263.41 Mn |
| 8 | 111 | 31.31 Mn | -27.44 Mn | 18.18 Mn |
| 9 | Cosmos Health | 13.28 Mn | 10.84 Mn | 1.51 Mn |
| 10 | Cellyan Biotechnology | 6.70 Mn | 6.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.78 Mn |
| Mar 31, 2026 | 3.78 Mn |
| Sep 30, 2025 | 5.09 Mn |
| Sep 30, 2025 | 5.09 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Mar 31, 2024 | 3.70 Mn |